Arbutus Biopharma
ABUS
53 hedge funds and large institutions have $207M invested in Arbutus Biopharma in 2017 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 8 closing their positions.
56% more capital invested
Capital invested by funds: $133M → $207M (+$74.3M)
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
6% more funds holding
Funds holding: 50 → 53 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
7.04% less ownership
Funds ownership: 67.03% → 60% (-7%)
17% less call options, than puts
Call options by funds: $141K | Put options by funds: $169K
Top Buyers
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$961K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$535K |
| 3 |
Morgan Stanley
New York
|
+$404K |
| 4 |
RI
RTW Investments
New York
|
+$241K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$224K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SIM
51
Sonora Investment Management
Tucson,
Arizona
| $124 | – | – | – |
|
|
SM
52
Sabby Management
Miami Beach,
Florida
| – | -$895K | -248,600 | Closed |
|
53
Goldman Sachs
New York
| – | -$330K | -91,706 | Closed |
|
54
Citadel Advisors
Miami,
Florida
| – | -$52K | -14,428 | Closed |
|
55
Ameriprise
Minneapolis,
Minnesota
| – | -$48K | -13,349 | Closed |
|
56
Simplex Trading
Chicago,
Illinois
| – | -$8.19K | -1,914 | Closed |
|
57
Creative Planning
Overland Park,
Kansas
| – | -$4K | -1,050 | Closed |
|
|
RFM
58
Royal Fund Management
Lady Lake,
Florida
| – | -$2K | -800 | Closed |
|
59
US Bancorp
Minneapolis,
Minnesota
| – | -$1K | -200 | Closed |
|
|
HNB
60
Huntington National Bank
Columbus,
Ohio
| – | +$428 | +100 | New |
|
ABUS Hedge Fund Activity: Q3 2017 in Review
53 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2017, worth a combined $207M — up 56% from $133M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ABUS positions and 8 closed out — a net gain of 4 holders — while 15 added to existing stakes and 15 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $961K. The largest seller was Ladenburg Thalmann Financial Services, cutting an estimated $15.1M.
- 53 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2017, up from 50 in Q2 2017.
- Funds reported $207M of Arbutus Biopharma stock for Q3 2017, up 56% quarter-over-quarter.
- 12 funds opened new Arbutus Biopharma positions in Q3 2017 and 8 closed out, a net change of +4 holders.
- The largest Arbutus Biopharma buyer in Q3 2017 was Point72 Asset Management, an estimated $961K added.
- The largest Arbutus Biopharma seller in Q3 2017 was Ladenburg Thalmann Financial Services, an estimated $15.1M sold.
Based on aggregated 13F filings for Q3 2017.